Health care giant Johnson & Johnson says it plans to expand its manufacturing presence in North Carolina, adding 120 jobs in the Triangle.
The company said in a statement that it is increasing its presence in Holly Springs with a 160,000-square-foot plant at a biopharmaceutical manufacturing site owned by Fujifilm Diosynth Biotechnologies.
Other WRAL Top Stories
J&J’s $2 billion commitment would come over the next 10 years, the company said in a statement this week. In the coming months, the New Brunswick, New Jersey-based company expects to disclose plans for additional manufacturing in the U.S. In March, J&J said it would invest $55 billion to support U.S. manufacturing, research and development, and technology investments over the next four years.
Holly Springs officials said in 2023 that Janssen, a Johnson & Johnson company, would be the first tenant at Fujifilm’s $2 billion campus. It wasn’t immediately clear if the J&J investment announced this week was related to the Janssen project. Spokespeople for Fujifilm and J&J didn’t immediately respond to requests for more information.
Johnson & Johnson has been expanding rapidly in North Carolina with the help of state incentives. State and local officials in October approved economic incentives packages worth a combined $79.9 million to lure a J&J subsidiary to Wilson.
J&J said Thursday that construction of the Wilson facility is ongoing. The facility is expected to employ more than 500 people when fully operational and create about 5,000 construction jobs during the site development. The company initially was expected to employ 420 employees. The company expects to invest up to $2 billion in that project, state officials previously said.
The Wilson plant is expected to expand production of Johnson & Johnson’s biologic medicines oncology, immunology and neuroscience, advancing the company’s strategy of developing dozens of novel therapies, the company previously said.